ES2578404T3 - Moduladores de la indolamina 2,3-dioxigenasa, y métodos de uso de los mismos - Google Patents

Moduladores de la indolamina 2,3-dioxigenasa, y métodos de uso de los mismos Download PDF

Info

Publication number
ES2578404T3
ES2578404T3 ES12178315.3T ES12178315T ES2578404T3 ES 2578404 T3 ES2578404 T3 ES 2578404T3 ES 12178315 T ES12178315 T ES 12178315T ES 2578404 T3 ES2578404 T3 ES 2578404T3
Authority
ES
Spain
Prior art keywords
amino
methyl
crarb
nrg1rh1
hydroximino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12178315.3T
Other languages
English (en)
Inventor
Andrew P. Combs
Eddy W. Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2578404(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Application granted granted Critical
Publication of ES2578404T3 publication Critical patent/ES2578404T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un compuesto de Fórmula:**Fórmula** o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento del cáncer en combinación con un anticuerpo anti-PD-1, en el que: W, X1 y X2 se seleccionan independientemente entre (CRaRb)t, (CRaRb)uO(CRaRb)v, (CRaRb)uC(O)(CRaRb)v, (CRaRb)uC(O)NRc(CRaRb)v, (CRaRb)uC(O)O(CRaRb)v, (CRaRb)uC(S)(CRaRb)u, (CRaRb)uC(S)NRc(CRaRb)v, (CRaRb)uS(O)(CRaRb)v, (CRaRb)uS(O)NRc(CRaRb)v, (CRaRb)uS(O)2(CRaRb)v, (CRaRb)uS(O)2NRc(CRaRb)v, (CRaRb)uNRc(CRaRb)v, y (CRaRb)uC(>=NRd)NRc(CRaRb)v; R2 es H, alquilo C1-6 , o cicloalquilo C3-7; R3a y R5a se seleccionan independientemente entre alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo, cicloalquilo, heteroarilo y heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente entre halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, Cy1, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(>=NRi)NRg1Rb1, NRg1C(>=NR')NRg1Rb1, P(Rfl)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rb1, S(O)2Rf1, y S (O)2NRg1Rh1; R3b es arilo o heteroarilo cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente entre halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, hidroxialquilo C1-4, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(>=NRi)NRg1Rh1, NRg1C(>=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S (O)2Rf1, y S(O)2NRg1Rh1; R5b es H, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo donde dicho alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo esta cada uno opcionalmente substituido por 1, 2, 3, 4 o 5 sustituyentes independientemente seleccionados entre halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, hidroxialquilo C1-4, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(>=NRi)NRg1Rh1, NRg1C(>=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1, y S(O)2NRg1Rh1; Cy1 y Cy2 son independientemente seleccionados entre arilo, heteroarilo, cicloalquilo y heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente entre halo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, CN, NO2, ORe3, SRe3, C(O)Rf3, C(O)NRg3Rh3, C(O)ORe3, OC(O)Rf3, OC(O)NRg3Rb3, NRg3Rh3, NRg3C(O)Rh3, NRg3C(O)ORe3, C(>=NRi)NRg1Rh1, NRg1C(>=NRi)NRg1Rh1, P(Rf3)2, P(ORe3)2, P(O)Re3Rf3, P(O)ORe3ORf3, S(O)Rf3, S(O)NRgRh3, S(O)2Rf3, y S(O)2NRg3Rh3; Ra y Rb se seleccionan independientemente entre H, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, CN, NO2, ORe4, SRe4, C(O)Rf4, C(O)NR g4 R h4, C(O)ORe4, OC(O)Rf4, OC(O)NRg4Rh4, NRg4Rh4, NRg4C(O)Rh4, NRg4C(O)ORe4, C(>=NRi)NRg1Rh1, NRg1C(>=NRi)NRg1Rh1, P(Rf4)2, P(ORe4)2, P(O)Re4Rf4, P(O)ORe4ORf4, S(O)Rf4, S(O)NRg4Rh4, S(O)2Rf4, y S(O)2NRg4Rh4; Rc es H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, arilalquilo, o cicloalquilalquilo; Rd es H, ORd1, CN o NO2; Rd1 es H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, arilalquilo, o cicloalquilalquilo; Re1, Re3, y Re4 se seleccionan independientemente entre H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, (alcoxiC1-6)-alquilo C1-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo y heterocicloalquilalquilo; Rf1, Rf3, y Rf4 se seleccionan independientemente entre H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo y heterocicloalquilo; Rg1, Rg3, y Rg4 se seleccionan independientemente de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, arilalquilo, y cicloalquilalquilo; Rh1, Rh3, y Rh4 se seleccionan independientemente de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, arilalquilo, y cicloalquilalquilo; o Rg1 y Rh1 o junto con el átomo de N al que están unidos forman un grupo de 4, 5, 6 o 7 miembros de heterocicloalquilo; o Rg3 y Rh3 o junto con el átomo de N al que están unidos forman un grupo de 4, 5, 6 o 7 miembros de heterocicloalquilo; o Rg4 y Rh4 o junto con el átomo de N al que están unidos forman un grupo de 4, 5, 6 o 7 miembros de heterocicloalquilo; Ri es H, CN, o NO2; a es 0 o 1; b es 0 o 1; n es 0 o 1; p es 0 o 1; t es 1, 2, 3, 4, 5 o 6; u es 0,1, 2, 3, 4, 5 o 6; y v es 0, 1, 2, 3, 4, 5 o 6.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
en un grado útil de pureza de una mezcla de reacción, y preferiblemente capaz de formulación en un agente terapéutico eficaz.
Se aprecia además que ciertas características de la invención, que están, para mayor claridad, descritas en el contexto de realizaciones separadas, también pueden proporcionarse en combinación en una única realización. A la inversa, diversas características de la invención que están, para mayor brevedad, descritas en el contexto de una única realización, también pueden proporcionarse separadamente o en cualquier subcombinación adecuada.
Tal como se utiliza aquí, el término "alquilo" se refiere a un grupo hidrocarbonado saturado que es de cadena lineal o ramificada. Ejemplos de grupos alquilo incluyen metilo (Me), etilo (Et), propilo (por ejemplo, n-propilo e isopropilo), butilo (por ejemplo, n-butilo, isobutilo, t-butilo), pentilo (por ejemplo, n-pentilo, isopentilo, neopentilo), y similares. Un grupo alquilo puede contener de 1 a aproximadamente 20, de 2 a aproximadamente 20, de 1 a aproximadamente 10, de 1 a aproximadamente 8, de 1 a aproximadamente 6, de 1 a aproximadamente 4, o de 1 a aproximadamente 3 átomos de carbono.
Como se usa en la presente memoria, "alquenilo" se refiere a un grupo alquilo que tiene uno o más dobles enlaces carbono-carbono. Ejemplos de grupos alquenilo incluyen etenilo, propenilo, y similares.
Como se usa en la presente memoria, "alquinilo" se refiere a un grupo alquilo que tiene uno o más triples enlaces carbono-carbono. Ejemplos de grupos alquinilo incluyen etinilo, propinilo, y similares.
Como se usa en este documento, "haloalquilo" se refiere a un grupo alquilo que tiene uno o más sustituyentes halógeno. Ejemplos de grupos haloalquilo incluyen CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, y similares.
Como se usa en la presente memoria, los grupos "carbociclilo" son restos hidrocarbonados cíclicos saturados (es decir, que no contienen enlaces dobles o triples) o insaturados (es decir, que contienen uno o más enlaces dobles o triples). Los grupos carbociclilo pueden ser mono o policíclicos (por ejemplo, que tienen 2, 3 o 4 anillos fusionados o espirociclos). Ejemplos de grupos carbociclilo incluyen ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, cicloheptilo, ciclopentenilo, 1,3-ciclopentadienilo, ciclohexenilo, norbornilo, norpinilo, norcarnilo, adamantilo, fenilo, y similares. Los grupos carbocíclico pueden ser aromáticos (por ejemplo, "arilo") o no aromáticos (por ejemplo, "cicloalquilo"). En algunas realizaciones, los grupos carbociclilo pueden tener de aproximadamente 3 a aproximadamente 30, de aproximadamente 3 a aproximadamente 20, de aproximadamente 3 a aproximadamente 10, o de aproximadamente 3 a aproximadamente 7 átomos de carbono.
Como se usa en este documento, "arilo" se refiere a hidrocarburos aromáticos monocíclicos o policíclicos (por ejemplo, que tienen 2, 3 o 4 anillos fusionados) tales como, por ejemplo, fenilo, naftilo, antracenilo, fenantrenilo, indanilo, indenilo, y similares . En algunas realizaciones, los grupos arilo tienen de 6 a aproximadamente 20 átomos de carbono.
Como se usa aquí, "cicloalquilo" se refiere a carbociclos no aromáticos incluyendo alquilo ciclado, alquenilo, y alquinilo. Los grupos cicloalquilo pueden incluir sistemas de anillos mono o policíclicos (por ejemplo, que tienen 2, 3 o 4 anillos fusionados), incluyendo espirociclos. En algunas realizaciones, los grupos cicloalquilo pueden tener de 3 a aproximadamente 20 átomos de carbono, de 3 a aproximadamente 14 átomos de carbono, de 3 a aproximadamente 10 átomos de carbono, o de 3 a 7 átomos de carbono. Los grupos cicloalquilo pueden tener además 0, 1, 2, o 3 dobles enlaces y/o 0, 1, o 2 enlaces triples. También se incluyen en la definición de cicloalquilo los restos que tienen uno o más anillos aromáticos fusionados (es decir, que tienen un enlace en común con) al anillo cicloalquilo, por ejemplo, derivados benzo de pentano, penteno, hexano, y similares. Uno o más átomos de carbono formadores de anillo de un grupo cicloalquilo pueden estar oxidados, por ejemplo, contando con un sustituyente oxo o sulfuro. Ejemplos de grupos cicloalquilo incluyen ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, cicloheptilo, ciclopentenilo, ciclohexenilo, ciclohexadienilo, cicloheptatrienilo, norbornilo, norpinilo, norcarnilo, adamantilo, y similares.
Como se usa en este documento, "heterociclilo" o "heterociclo" se refiere a un grupo cíclico saturado o insaturado en el que uno o más de los átomos que forman el anillo son heteroátomos tales como O, S, o N. Los grupos heterociclilo incluyen sistemas de anillo mono o policíclicos. Los grupos heterociclilo pueden ser aromáticos (por ejemplo, "heteroarilo") o no aromáticos (por ejemplo, "heterocicloalquilo"). Los grupos heterociclilo pueden caracterizarse por tener 3-14, 3-12, 3-10, 3-7, o 3-6 átomos formadores de anillo. En algunas realizaciones, los grupos heterociclilo pueden contener, además de al menos un heteroátomo, de aproximadamente 1 a aproximadamente 13, aproximadamente 2 a aproximadamente 10, o aproximadamente 2 a aproximadamente 7 átomos de carbono y se pueden conectar/enlazar a través de un átomo de carbono o un heteroátomo. En realizaciones adicionales, el heteroátomo puede estar oxidado (por ejemplo, tener un sustituyente oxo o sulfido) o un átomo de nitrógeno pueden estar cuaternizado. Los ejemplos de grupos heterociclilo incluyen morfolino, tiomorfolino, piperazinilo, tetrahidrofuranilo, tetrahidrotienilo, 2,3-dihidrobenzofurilo, 1,3-benzodioxol, benzo-1 ,4-dioxano, piperidinilo, pirrolidinilo, isoxazolidinilo, isotiazolidinilo, pirazolidinilo, oxazolidinilo, tiazolidinilo, imidazolidinilo , y similares, así como cualquiera de los grupos enumerados a continuación para "heteroarilo" y "heterocicloalquilo".
imagen8
imagen9
imagen10
imagen11
imagen12
Las oximas adicionales amida se pueden sintetizar como se describe en el Esquema 5 (X es un grupo saliente). El reordenamiento de la oxima amida 7 puede dar 16 que se puede convertir a 17 con nitrito de sodio en HC1. La reacción de 17 con aminas puede dar compuestos tales como 18.
imagen13
Los compuestos adicionales pueden sintetizarse como se muestra en el Esquema 6. El acoplamiento de la amida 8 puede dar 19 que puede ser tratado con pentacloruro de fósforo y luego se reduce con un hidruro tal como
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
TABLA 1
Ex. No .
Estructura Nombre Prep. Metodo MS (M+1)
71
N-{4 -[(E, Z) -[(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-ciclopentano carboxamida Ex. 35 350.0
72
N-{4 -[(E, Z) -[(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il)]] trifluoroacetato nicotinamida Ex. 35 359.0
73
N-{4 - [(E, Z) -[(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-isonicotinamida trifluoroacetato Ex. 35 359.0
74
N-{4 - [(E, Z) -[(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-2-metoxibenzamida Ex. 35 388.1
75
N-{4 - [(E, Z) -[(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-3-metoxibenzamida Ex. 35 387.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
76
N-{4 - [(E, Z) - [(3-clorofenil) amino] (hydroximino) metil] -1,2,5oxadiazol-3-il}-4-metoxibenzamida Ex. 35 388.0
77
2-Cloro-N-{4 - [(E, Z) - [(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-benzamida Ex.35 391.9
78
3-Cloro-N-{4 - [(E, Z) - [(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-benzamida Ex. 35 391.9
79
imagen48 4-Cloro-N-{4 - [(E, Z) - [(3-clorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-benzamida Ex. 35 391.9
80
N-{4 - [(E, Z) - [(3-cloro-fenil) amino] (hydroximino) metil] -1,2,5 oxadiazol-3-il} -3,3dimetilbutanamida Ex. 35 352.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
81
4-Amino-N-(3-bromofenil)-Nhidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 298.0, 300.0
82
imagen49 4-Amino-N-(3-bromo-4metilfenil)-N'-hidroxi-1 ,2,5oxadiazole-3-carboximidamida Ex. 1 312.1, 314.1
83
imagen50 4-Amino-N-(3-cloro-4metoxifenil)-N'-hidroxi-1, 2,5 oxadiazol-3-carboximidamida Ex. 1 284.1
84
imagen51 4-Amino-N-(3,5diniethylphenyl)-N'-hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 248.2
85
4-Amino-N '-hidroxi-N-(2metilbenzil) -1,2,5-oxadiazole3-carboximidamida Ex. 1 248.2
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
86
4-Amino-N '-hidroxi-N-(3metilbenzil) -1,2,5-oxadiazole3-carboximidamida Ex. 1 248.2
87
4-Amino-N '-hidroxi-N-(4metilbenzil) -1,2,5-oxadiazole3-carboximidamida Ex. 1 248.2
88
4-Amino-N '-hidroxi-N-[2 - (trifluorometil)-benzil] -1,2,5oxadiazol-3-carboximidamida Ex. 1 302.1
89
4-Amino-N '-hidroxi-N-[4 - (trifluorometil)-benzil] -1,2,5oxadiazol-3-carboximidamida Ex. 1 302.1
90
4-Amino-N-(3-etilfenil)-N'hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 248.1
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
91
4-Amino-N-(3,4-diclorofenil)-N'hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 288.1
92
imagen52 4-Amino-N-(3,5-diclorofenil)-N'hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 288.1
93
4-Amino-N-bifenil-3-il-N '-hidroxi1 ,2,5-oxadiazole-3 carboximidamida Ex. 1 296.1
94
4-Amino-N-(2-fluorofenil)-N'hidroxi-1, 2,5 -oxadiazol-3carboximidamida Ex. 1 238.1
95
4-Amino-N-(3-cloro-4-metilbenzil)-N'-hidroxi-1 ,2,5oxadiazole-3-carboximidamida Ex.1 282.1
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
96
4-Amino-N-(4-fluorofenil)-N'hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 238.1
97
4-Amino-N-(2,3-dimetilfenil)N'-hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 248.2
98
imagen53 N-{4 - [(E, Z) - [(3-cloro-fenil) amino] (hidroxi-imino) metil] 1,2,5-oxadiazol-3-il}-4iodobenzamida Ex. 35 483.8
99
4-Amino-N-(4-cloro-3metilfenil)-N'-hidroxi-1 ,2,5oxadiazole-3-carboximidamida Ex. 1 268.2
100
4-Amino-N '-hidroxi-N-[3 (metiltio)fenil] -1,2,5oxadiazole-3-carboximidamida Ex. 1 266.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
101
4-Amino-N-(3-cloro-2-metilfenil)N'-hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 268.1
102
4-Amino-N-(3-fluoro-2metilfenil)-N'-hidroxi-1 ,2,5oxadiazole-3-carboximidamida Ex. 1 252.1
103
4-Amino-N '-hidroxi-N-(3vinilfenil) -1,2,5-oxadiazole-3carboximidamida Ex.1 246.1
104
imagen54 4-Amino-N-(3-etinilfenil)-N'hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 244.0
105
4-Amino-N-(4-fluoro-3metilfenil)-N'-hidroxi-1 ,2,5oxadiazole-3-carboximidamida Ex. 1 252.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Meto do MS (M+1)
106
4-Amino-N '-hidroxi-N-(3-iodofenil) 1,2,5-oxadiazole-3-carboximidamida Ex. 1 345.9
107
4-Amino-N '-hidroxi-N-(3isopropilfenil) -1,2,5-oxadiazole-3carboximidamida Ex. 1 262.2
108
4-Amino-N-(3-bromo-4-fluorofenil)N'-hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 316.1
109
4-Amino-N '-hidroxi-N-(4-fenilbutil) 1,2,5-oxadiazole-3-carboximidamida Ex. 1 276.2
110
4-Amino-N '-hidroxi-N-[3 - (1,3oxazol-5-il) fenil] -1,2,5-oxadiazole3-carboximidamida Ex. 1 287.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metod o MS (M+1 )
111
N-{4 -[(E, Z) -[(3-cloro-fenil) amino] (hydroxyim ino) metil] -1,2,5-oxadiazol-3-il}-4cianobenzamida Ex. 35 382. 9
112
imagen55 4-Amino-N’-hydroxy-N-[1phenylethyl] -1,2,5-oxadiazole-3carboximidamide Ex. 1 248. 2
113
imagen56 4-Amino-N’-hydroxy-N-1-naphthyl1,2,5-oxadiazole-3carboximidamide Ex. 1 270. 2
114
imagen57 4-Amino-N '-hidroxi-N-2-naftil-1 ,2,5-oxadiazole-3-carboximidamida Ex. 1 270. 2
115
4-Amino-N-(3-chloro-2fluorophenyl)-N’-hydroxy-1,2,5oxadiazole-3-carboximidamide Ex. 1 272. 1
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
116
N-{4 - [(E, Z) - {[4-Fluoro-3 (trifluorometil) fenil] amino} (Hidroxi-imino) metil] -1,2,5 - oxadiazol-3-il} nicotinamida trifluoroacetato Ex. 35 411.1
117
N-{4 - [(E, Z) - {[4-Fluoro3 - (trifluorometil) fenil] amino} (Hidroximino) metil] -1,2,5 -oxadiazol-3-il} isonicotinamida trifluoroacetato Ex. 35 411.1
118
4-Amino-N-(3-ciclopropilfenil)N'-hidroxi-1,2,5-oxadiazole-3carboximidamida Ex. 1 260.2
119
imagen58 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hydroximino) metil] -1,2,5oxadiazol-3-il}-benzamida Ex. 35 420.0 , 421.9
120
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-nicotinamida trifluoroacetato Ex. 35 420.9 , 422.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
121
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hydroximi no) metil] -1,2,5-oxadiazol-3-il}isonicotinamida trifluoroacetato Ex. 35 421.0, 422.9
122
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) aminodroxyimino) metil] -1,2,5-oxadiazol-3-il}-4cianobenzamida Ex. 35 444.9, 446.9
123
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-3cianobenzamida Ex. 35 445.0, 447.0
124
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-2-naftamida Ex. 35 470.0, 472.0
125
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-1-naftamida Ex. 35 470.0, 472.0
imagen59
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
131
terc-butil {4 - [({4 - [(E, Z) - [(3bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} amino)carbonil ] benzil} carbamato Ex. 41 548.9, 551.0
132
imagen60 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-1-benzotiofeno2-carboxamida Ex. 41 475.9, 477.9
133
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -1,3-tiazole-4carboxamida Ex. 41 426.9, 428.9
134
imagen61 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-1-benzotiofeno3-carboxamida Ex. 41 475.9, 477.9
135
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroxiimino) metil] -1,2,5-oxadiazol3-il}-tiofeno-3-carboxamida Ex. 41 425.8, 427.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
136
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-1H-imidazole2carboxamide Ex. 41 409.9, 411.9
137
imagen62 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-4-metil-1 ,2,3tiadiazole-5-carboxamida Ex. 41 441.9, 443.9
138
N-{4 - [(E, Z) - [(3,-Bromo-4- fluorofenil) mino] (hidroxiimino) metil] -1,2,5-oxadiazol3-il} carboxamida -1,2,3tiadiazole-4 Ex. 41 427.9, 429.9
139
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2,1benzisoxazole-3-carboxamida Ex. 41 460.9, 462.9
140
imagen63 4 - (aminometil)-N-{4 - [(E, Z) - [(3-bromo-4-f luorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-benzamida trifluoroacetato Ex. 41 448.9, 450.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
141
imagen64 N-(3-Bromo-4fluorofenil)-N'-hidroxi-4-({[(2feniletil) amino] carbonil}-amino) -1,2,5-oxadiazole-3- carboximidamida Ex. 43 463.0, 465.0
142
imagen65 N-(3-Bromo-4-fluorofenil) -4 - {[ (ciclopentilamino) carbonil] a mino}-N '-hidroxi-1 ,2,5oxadiazole-3-carboximidamida Ex. 43 426.9, 428.9
143
imagen66 N-(3-Bromo-4-fluoro-fenil) -4 - ({[ (3-cianof enil)-carbonil] amino} a mino)-N'-hidroxi-1, 2,5 - oxadiazol-3-carboximidamida Ex. 43 459.9, 461.9
144
imagen67 N-{4 - [(E, Z) - [(3-Bromo-4f luorof enil) amino] (hidroimino) metil] -1,2,5-oxadiazol-3-il}-3terc-butil-1-metil-1H-pirazole-5carboxamida Ex. 35 480.0, 482.0
145
imagen68 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol-3-il}-2metoxiacetamida Ex. 35 387.9, 389.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
146
imagen69 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} ciclopentanocarboxamida Ex. 35 412.0, 413.9
147
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-butanamida Ex. 35 385.9 388.0
148
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-propanamida Ex. 35 386.0 387.9
149
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-propanamida Ex. 35 371.9, 373.9
150
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} ciclohexanocarboxamida Ex. 35 426.0, 427.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
151
4-Amino-N-(2,3-diclorofenil)-N'-hidroxi-1,2,5-oxadiazol-3carboximidamida Ex. 47 288.0
152
4-Amino-N-(3-clorofenil)-N'hidroxi-N-metil-1,2,5oxadiazol-3 carboximidamida Ex.1 268.1
153
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximi no) metil] -1,2,5-oxadiazol-3il}-1H-bencimidazol-5carboxamida Ex. 35 460.0, 462.0
154
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-2fenoxiacetamida Ex. 35 449.9, 451.8
155
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} ciclobutanocarboxamida Ex. 35 398.0, 400.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
156
imagen70 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 3-metilbutanamida Ex. 35 400.0, 402.0
157
imagen71 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 3-piridin-3-il propanamida trifluoroacetato Ex. 35 449.0, 450.9
158
imagen72 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} quinolin-6-carboxamida Ex. 35 470.9, 472.9
159
imagen73 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 2 - (4-clorofenoxi) acetamida Ex. 35 483.9, 485.9
160
imagen74 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (4bromofenoxi) acetamida Ex. 35 527.8, 529.9, 531.8
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
161
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (4fluorofenoxi) acetamida Ex. 35 468.0, 470.0
162
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (4-tercbutilfenoxi) acetamida Ex. 35 506.0, 508.0
163
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (3clorofenoxi) acetamida Ex. 35 483.9, 485.9
164
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (3,4diclorofenoxi) acetamida Ex. 35 518.4, 519.9, 522.0
165
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (2-naftiloxi) acetamida Ex. 35 500.1, 502.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
166
imagen75 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (2,3diclorofenoxi) acetamida Ex. 35 517.8, 519.8, 521.8
167
imagen76 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidrox imino) metil] -1,2,5-oxadiazol3-il} -2 - (4-clorofenoxi)-2metilpropanamida Ex. 35 511.9, 513.9
168
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (2clorofenoxi) acetamida Ex. 35 483.8, 485.9
169
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (3metoxifenoxi) acetamida Ex. 35 480.0, 481.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
170
imagen77 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (4metoxifenoxi) acetamida Ex. 35 479.9, 481.9
171
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (2metoxifenoxi) acetamida Ex. 35 480.0, 482.0
172
Bencil {4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}carbamato Ex. 35 449.9, 451.9
173
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}acetamida Ex. 35 357.9, 359.9
174
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} piperidina-1carboxamida Ex. 48 427.0, 429.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
175
imagen78 N-(3-Bromo-4-fluorofenil) -4 - ({[(3-cianofenil) (metil) amino carbonilo coche]} amino)-N'hidroxi-1, 2,5 -oxadiazol-3carboximidamida Ex. 48 473.9, 476.0
176
imagen79 4-amino-N'-hidroxi-N-(6metilpiridin-2-il) -1,2,5oxadiazol-3-carboximidamida trifluoroacetato Ex. 45 235.1
177
imagen80 4 - ({[Bencil (metil) amino] de carbonoil} amino)-N-(3-bromo4-'fluorofenil)-N'-hidroxi-1,2,5oxadiazol-3-carboximidamida Ex. 48 463.0, 464.9
178
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2fenilacetamida Ex. 35 434.0, 436.0
179
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (3metoxifenil) acetamida Ex.35 464.0, 466.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
180
N-(3-Bromo-4-fluorofenil) -4 - ({[(3-cianofenil) (metil) amino] carbonil} amino)-N'-hidroxi-1, 2,5 - oxadiazol-3carboximidamida Ex. 48 473.9, 476.0
181
imagen81 4-amino-N'-hidroxi-N-(6metilpiridin-2-il) -1,2,5oxadiazol-3 carboximidamida trifluoroacetato Ex. 45 235.1
182
imagen82 4 - ({[Bencil (metil) amino] de carbono il} amino)-N-(3-bromo-4'fluorofenil)-N'-hidroxi1,2,5-oxadiazol-3carboximidamida Ex. 48 463.0, 464.9
183
imagen83 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 2-fenilacetamida Ex. 35 434.0, 436.0
184
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} -2 - (3-metoxifenil) acetamida Ex.35 464.0, 466.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
185
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (4-bromofenil) propanamida Ex. 35 525.8, 527.8, 529.8
186
imagen84 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadinol-3-il} - 3 - (4-clorofenil) propanamida Ex. 35 481.9, 483.9
187
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil) 1,2,5-oxadiazol-3-il} - 3 - (3-clorofenil) propanamida Ex.35 481.9, 483.9
188
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (2-fluorofenil) propanamida Ex. 35 466.0, 467.9
189
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (3-fluorofenil) propanamida Ex. 35 465.9, 467.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
190
imagen85 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (2-clorofenil) propanamida Ex. 35 481.9, 483.9
191
imagen86 N-{4 - [(E, 2) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (3-metilfenil) propanamida Ex. 35 462.0, 464.0
192
imagen87 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (3 - (trifluorometil) fenil) propanamida Ex. 35 515.9, 517.9
193
imagen88 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (4-fluorofenil) propanamida Ex. 35 465.9, 468.0
194
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3 - (2-metoxifenil) propanamida Ex. 35 477.9, 479.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1 )
195
imagen89 N-{4 - [(E, Z) - [(3bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol3-il} -3 - (3-metoxifenil) propanamida Ex. 35 477.9 480.0
196
imagen90 N-{4 - [(E, Z) - [(3bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol3-il} -3 - (4-metoxifenil) propanamida Ex. 35 477.9 479.9
197
N-{4 - [(E, Z) - [(3bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol3-il} -3 - (4-metilfenil) propanamida Ex. 35 462.0 463.9
198
N-{4 - [(E, Z) - [(3bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol3-il} -3 - [4 (trifluorometil) fenil] propanamida Ex. 35 515.9 517.9
199
3 - [2,5-bis (trifluorometil)fenil]-N{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} propanamida Ex. 35 583.9 585.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
200
imagen91 3 - [3,5-bis (trifluorometil) fenil]-N-{4 - [(E, Z) - [(3bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol-3il} propanamida Ex. 35 583.9, 585.9
201
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 2-metil-3fenilpropanamida Ex. 35 462.0, 464.0
202
imagen92 2-bencil-N-{4 - [(E, Z) - [(3-bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol-3il} -3,3dimetilbutanamida Ex. 35 504.0, 506.0
203
imagen93 4-Amino-N-(5-cloro-2metoxifenil)-N-hidroxi1,2,5-oxadiazol-3carboximidamida Ex. 1 284.1
204
imagen94 4-Amino-N-(5-cloro-2-metilfenil)-N'-hidroxi1,2,5-oxadiazol-3carboximidamida Ex.1 Ex. 47 268.1 299.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
205
4-Amino-N-(5-cloro-2-nitrofenil)-N'-hidroxi1,2,5-oxadiazol-3carboximidamida Ex. 47 299.0
206
4-Amino-N-(5-cloro-2fluorofenil)-N'-hidroxi1,2,5-oxadiazol-3carboximidamida Ex. 47 272.1
207
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 1 - [4 - (trifluorometil) pirimidin-2-il] piperidina4-carboxamida Ex. 35 573.0, 575.0
208
1-bencil-N-{4 - [(E, Z) - [(3-bromo-4-fluorofenil) amino] (no hidroximi) metil] -1,2,5-oxadiazol-3il}-3-terc-butil-1H-pirazol5-carboxamida Ex. 35 556.0, 558.0
209
2 - (benciloxi)-N-{4 - [(E, Z) - [(3-bromo-4 fluorofenil) amino] (hidroximino) metil] 1,2,5 -oxadiazol-3-il} acetamida Ex. 35 463.9, 466.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
210
imagen95 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -1 - (4clorofenil ) ciclopentano carboxamida Ex. 35 521.9, 523.9
211
imagen96 N-{4-[(E,Z)-[(3-Bromo-4fluorophenyl)amino](hidrox imino)methyl]-1,2,5oxadiazol-3-yl}-3phenoxybenzamide Ex. 35 511.9, 513.9
212
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2,4,6trichlorobenzamide Ex. 35 521.8, 523.8, 525.8
213
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il)-2metoxibenzamida Ex. 35 449.9, 451.9
214
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 3-metoxibenzamida Ex. 35 449.9, 451.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
215
imagen97 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 2,2 difenilacetamida Ex. 35 510.0 512.0
216
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -4 - (trifluorometoxi) benzamida Ex. 35 503.9 505.9
217
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 4-metoxibenzamida Ex. 35 449.9 451.8
218
imagen98 N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 3,4-dimetoxibenzamida Ex. 35 479.9 481.9
219
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (2nitrofenoxi) acetamida Ex. 35 494.9, 496.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
220
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 2-cloronicotinamida trifluoroacetato Ex. 35 454.9 456.9
221
imagen99 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} bifenil-4-carboxamida Ex. 35 496.0 497.9
222
imagen100 N-{4 - [(E, Z) - [(3-bromo4-fenilo fluoro)-amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} -2 - (2,6-diclorobencil) -1,3tiazol-4-carboxamida Ex. 35 584.8, 586.8, 588.8
223
imagen101 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il} -2,6dimetoxibenzamida Ex. 35 479.9, 482.0
224
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] (hidroximino) metil] 1,2,5-oxadiazol-3-il}-4nitrobeozamide Ex. 35 464.9, 466.9
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
225
imagen102 5-Bromo-N-{4 - [(E, Z) -[(3-bromo-4-fluorofenil) amino] - (hidroximino) metil] -1,2,5-oxadiazol-3il}trifluoroacetato nicotinamida Ex. 35 498.8, 500.8, 502.8
226
imagen103 N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] - (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 3,3-dimetilbutanamida Ex. 35 413.9, 415.9
227
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] - (hidroximino) metil] 1,2,5-oxadiazol-3-il} - 2 - (2-tienil) acetamida Ex. 35 439.9, 441.9
228
N-{4 - [(E, Z) - [(3-bromo4-fluorofenil) amino] - (hidroiimino) metil] 1,2,5-oxadiazol-3-il} - 4-fenilbutanamida Ex. 35 462.0, 464.0
229
4-Amino-N-(2-bromo-5- clorofenil)-N'-hidroxi1,2,5-oxadiazol-3carboximidamida Ex. 47 332.0, 334.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
230
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] - (hidroximino) metil] -1,2,5oxadiazol-3-il} - 2,2-dimetilpropanamida Ex. 35 400.0, 401.9
231
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 4 - (morfolin-4-il-metil) Benzamida trifluoroacetate Ex. 35 519.0, 521.0
232
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] - (hidroximino) metil] -1,2,5oxadiazol-3-il} - 4 - [(1,1 dioxidothiomorpholin-4-il) metil]benzamide trifluoroacetate Ex. 35 567.0, 569.0
233
N-{4 - [(E, Z) - [(3-bromo-4fluorofenil) amino] - (hidroximino) metil] -1,2,5oxadiazol-3-il} - 1 - (fenilacetil) piperidina4-carboxamida Ex. 53 545.0, 547.0
234
N-{4 - [(E, Z) - [(3-Bromo4-fluoro-fenil)amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -1 - (metilsulfonil) piperidina-4carboxamida Ex. 53 505.0, 507.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
235
N-{4 - [(E, Z) - [(3-Bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-2-piridin-4il-1 ,3-tiazol-4 carboxamide trifluoroacetate Ex. 35 504.0, 506.0
236
N-{4 - [(E, Z) - [(3-Bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 2-nitrobenzamida Ex. 35 464.9, 466.9
237
N-{4 - [(E, Z) - [(3-Bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-3nitrobenzamida Ex. 35 464.9, 466.9
238
N-{4 - [(E, Z) - [(3-Bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5trifoxadiazol-3-il}-1isopropylpiperidine-4carboxamida Ex. 55 469.0, 471.0
239
terc-butil 4 - {4 - [({4 - [(E, Z) - [(3 -bromo-4-f luorof enil) amino](hidroximino) metil] -1,2,5 -oxadiazol-3-il} amino) carbonil] -1,3tiazol-2-il}-piperidino-1carboxilato Ex. 51 510.0 512.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
240
imagen104 N-{4 - [(E, Z) - [(3-Bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2-fenil-1 ,3tiazol-4-carboxamida Ex. 35 502.9, 504.9
241
imagen105 N-{4 - [(E, Z) - [(3-Bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2-metil-1 ,3-tiazol-4-carboxamida Ex. 35 441.0, 443.0
242
imagen106 N-{4 - [(E, Z) - [(3-Bromo4-fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-2-piperidin4-il-1 ,3-tiazol-4 carboxamida cloridrato Ex. 52 510.0, 512.0
243
imagen107 N-{4 - [(E, Z) - [(3-Bromo4fluorofenil)amino](hidroxi mino) metil] -1,2,5oxadiazol-3-il} - 2 - (4-cianofenoxi)acetamida Ex. 57 475.0, 476.9
244
imagen108 terc-butil 3 - [({4 - [(E, Z) - [(3-bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol-3il}carbonil) amino]piperidina-1-carboxilato de etilo Ex. 51 527.0, 529.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
245
N-{4 - [(E, Z) - [(3-Bromo-4f luorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-3 - (3 nitrofenil) propanamida Ex. 51 493.0, 494.9
246
imagen109 N-{4 - [(E, Z) - [(3-Bromo-4f luorofenil) amino] (hidroximino)metil] -1,2,5oxadiazol-3-il} -2 - acetamida (3-nitrofenoxi) Ex. 51 494.9, 497.0
247
imagen110 N-{4 - [(E, Z) - [(3-Bromo-4 fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (4-nitrof enoxi) acetamida Ex. 51 494.9, 496.9
248
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}piperidina-3carboxamida trifluoroacetato Ex. 52 426.9, 429.0
249
N-{4 - [(E, Z) - [(3-Bromo-4f luorofenil) amino] (hidroximino)metil] -1,2,5oxadiazol-3-il} -4-metil-2piridin-3-il-1, 3 - tiazol-5carboxamida trifluoroacetato Ex. 57 518.0, 520.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metod o MS (M+1)
N-{4 - [(E, Z) - [(3-Bromo-4
250
imagen111 f luorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -4-metil-1 ,3tiazol-5- carboxamida Ex. 57 441.0 443.0
2-Amino-N-{4 - [(E, Z) - [(3
251
bromo-4-fluorofenil)amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} - 1,3-tiazol-4carboxamida trifluoroacetato Ex. 57 442.0 444.0
N-{4 - [(E, Z) - [(3-Bromo-4
252
imagen112 fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -4-metil-2pirazin-2-il-1, 3 -tiazol-5carboxamida trifluoroacetato Ex. 51 519.0 521.0
N-{4 - [(E, Z) - [(3-Bromo-4
253
imagen113 f luorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -4-metil-2-[4 -(trifluorometil) fenil] -1,3tiazole-5-carboxamida Ex. 51 585.0 587.0
N-{4 - [(E, Z) - [(3-Bromo-4
254
f luorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2,4-dimetil-1 ,3-tiazol-5-carboxamida Ex. 57 455.0 457.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
255
imagen114 1-Acetil-N-{4 - [(E, Z) - [(3bromo-4- fluorof enil) amino] - (hidroximino) metil] -1,2,5oxadiazol-3-il}-pirrolidina-2carboxamida Ex. 51 454.9, 456.9
256
imagen115 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino metil] -1,2,5oxadiazol-3-il} -1,5-dimetil1H-pirazole-3- carboxamida Ex. 35 437.9, 439.9
257
imagen116 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5 oxadiazol-3-il}-5-cloro-1 metil-1H-pirazole-4 carboxamida Ex. 35 457.9, 459.9
258
imagen117 N-{4 - [(E, Z) - [(3-Bromo-4f luorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -1,3-dimetil1H-pirazole-5-carboxamida Ex.35 438.0, 440.0
259
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-1-metil-1Himidazol-2-carboxamida Ex. 51 424.1 426.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
260
4 - [(acetilamino) metil]-N-{4 - [(E,Z) - [(3-bromo-4-fluorofenil) amino] (hidroximino) metil] -1,2,5-oxadiazol-3-il}benzamida Ex. 56 491.0 493.0
261
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-4 metilpiperidina-4carboxamida trifluoroacetato Ex. 58 441.0 443.0
262
1-Acetil-N-{4 - [(E, Z) - [(3bromo-4- f luorof enil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-piperidina-3carboxamida Ex. 53 469.0 471.0
263
1-Acetil-N-{4 - [(E, Z) - [(3bromo-4-f luorof enil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-4 metilpiperidina-4carboxamida Ex. 53 483.0 485.0
264
imagen118 1-Acetil-N-{4 - [(E, Z) - [(3bromo-4-f luorof enil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-4-fenilpiperidina-4-carboxamida Ex. 53 545.0 547.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Meto do MS (M+1)
265
imagen119 4 - (benzilamino)-N-(3bromo-4-N'fluorofenil)hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex.49 406.1 408.0
266
imagen120 N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -1etilpiperidina-3-carboxamida trifluoroacetato Ex. 55 455.0 457.0
267
N-{4 - [(E, Z) - [(3-Bromo-4fluorofenil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il}-4-etilpiperazina-1 carboxamida trifluoroacetato Ex. 48 456.0 458.0
268
4-Acetil-N-{4 - [(E, Z) - [(3bromo-4-f luorof enil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} piperazina-1 carboxamida Ex. 48 470.0 472.0
269
imagen121 N-{4 - [(E, Z) - [(3-Bromo-4-f luorof enil) amino] (hidroximino) metil] -1,2,5oxadiazol-3-il} -2 - (1etilpiperidin-4-il) -1,3 -tiazol4carboxamida trifluoroacetato Ex. 55 538.0 540.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
270
imagen122 4-Amino-N-(3-ciano-4fluorofenil)-N'-hidroxi-1, 2,5 -oxadiazol-3carboximidamida Ex. 1 263.1
271
imagen123 N-(3-Bromo4fluorofenil)-N'- hidroxi4-[(1,3-tiazol-4-il-metil) amino] -1,2,5 oxadiazole-3carboximidamida Ex. 60 413.0 415.0
272
imagen124 N-(3-Bromo-4fluorofenil) -4 - [(4 cianobenzil) amino]-Nhidroxi-1 ,2,5oxadiazole-3 carboximidamida Ex. 60 431.0 433.0
273
imagen125 4-Amino-N-(3-cloro-5fluoro-fenil)-N'-hidroxi-1 ,2,5-oxadiazole-3carboximidamida Ex. 1 272.0
274
4-Amino-N-[3 - (dif luorometil) fenil]-N 'hidroxi-1 ,2,5 oxadiazole-3carboximidamida Ex. 1 270.1
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
275
imagen126 N-(3-Bromo-4 fluorofenil)-N'-hidroxi-4{[(1-metil-piperidin-4-il) metil] amino} -1,2,5oxadiazole trifluoroacetato-3carboximidamida Ex. 60 427.0 429.0
276
imagen127 N-(3-Bromo-4fluorofenil)-N '-hidroxi-4{[4 - (piperazin-1-il-metil)benzil] amino} -1,2,5 - oxadiazol-3 carboximidamida bis (trifluoroacetato) Ex. 60 504.0 506.0
277
imagen128 N-(3-Bromo-4-fluorofenil) -4 - ({4 - [(4-etilpiperazin1-il) metil]benzil} amino)-N '-hidroxi-1 ,2,5 oxadiazole-3carboximidamida bis (trifluoroacetato) Ex. 60 532.2 534.2
278
imagen129 4-Amino-N '-hidroxi-N-(3 -hidroxifenil) -1,2,5oxadiazole- 3carboximidamida Ex. 1 236.1
279
4-Amino-N-(3-cloro-4- fluorofenil)-N' (isobutiriloxi) - 1,2,5 oxadiazole-3- carboximidamida Ex. 67 342.0
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
280
imagen130 4-Amino-N-(3-cloro-4- fluorofenil)-N'-[(3 - metilbutanoil)-oxi] -1,2,5 -oxadiazol-3carboximidamida Ex. 67 356.0
281
4-amino-N'-(benziloxi)-N(3 -cloro-4-fluorofenil) 1,2,5 - oxadiazol-3carboximidamida Ex. 67 376.0
282
4-Amino-N-(3-cloro-4- fluorofenil)-N'-[(2,2 - dimetilpropanoil) oxi] 1,2,5 -oxadiazol-3carboximidamida Ex. 67 356.0
283
4-Amino-N-[3 - (cianometil) fenil]-N 'hidroxi-1, 2,5 -oxadiazol3-carboximidamida Ex. 67 259.1
284
4-Amino-N-(3-cyano-2fluorophenyl)-N’-hydroxy1,2,5-oxadiazole-3carboximidamide Ex. 1 263.1
TABLA 1
Ex. No.
Estructura Nombre Prep. Metodo MS (M+1)
285
imagen131 4-Amino-N '-hidroxi-N-[3 - (metoximetil) fenil] - 1,2,5-oxadiazole-3carboximidamida Ex. 1 264.1
286
imagen132 4-Amino-N '-hidroxi-N-[3 - (3-metoxiprop-1-in-1-il) fenil] -1,2,5-oxadiazole3-carboximidamida Ex. 70 287.9
287
imagen133 4-Amino-N '-hidroxi-N-(2metil-1,3-benzoxazol-4-il) -1,2,5-oxadiazole-3carboximidamida Ex. 1 275.0
288
imagen134 4-anilino-N-(3-bromo-4- fluorofenil)-N'-hidroxi-1, 2,5 -oxadiazol-3carboximidamida Ex. 69 392.0, 394.0
289
imagen135 N-(3-Bromo-4fluorofenil)-N'-hidroxi-4[(piridin-4-ilmetil)amino] 1,2,5-oxadiazole-3- trifluoroacetato carboximidamida Ex. 63 406.9, 408.9
imagen136
imagen137
imagen138
imagen139
imagen140

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
ES12178315.3T 2005-05-10 2006-05-09 Moduladores de la indolamina 2,3-dioxigenasa, y métodos de uso de los mismos Active ES2578404T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67950705P 2005-05-10 2005-05-10
US679507P 2005-05-10

Publications (1)

Publication Number Publication Date
ES2578404T3 true ES2578404T3 (es) 2016-07-26

Family

ID=37396891

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06759438T Active ES2401482T3 (es) 2005-05-10 2006-05-09 Moduladores de la indolamina 2,3-dioxigenasa y métodos de uso de los mismos
ES12178315.3T Active ES2578404T3 (es) 2005-05-10 2006-05-09 Moduladores de la indolamina 2,3-dioxigenasa, y métodos de uso de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES06759438T Active ES2401482T3 (es) 2005-05-10 2006-05-09 Moduladores de la indolamina 2,3-dioxigenasa y métodos de uso de los mismos

Country Status (32)

Country Link
US (6) US8034953B2 (es)
EP (3) EP3085697A1 (es)
JP (2) JP4990270B2 (es)
KR (2) KR101562549B1 (es)
CN (2) CN101212967A (es)
AR (1) AR054271A1 (es)
AU (1) AU2006244068B9 (es)
BR (2) BR122020016659B8 (es)
CA (1) CA2606783C (es)
CR (1) CR9485A (es)
CY (2) CY1113989T1 (es)
DK (2) DK1879573T3 (es)
EA (1) EA026785B1 (es)
ES (2) ES2401482T3 (es)
GE (1) GEP20217221B (es)
HR (2) HRP20130220T1 (es)
HU (1) HUE029214T2 (es)
IL (2) IL186957A (es)
ME (1) ME02461B (es)
MX (1) MX2007013977A (es)
MY (1) MY153424A (es)
NO (2) NO340487B1 (es)
NZ (1) NZ562919A (es)
PL (2) PL1879573T3 (es)
PT (2) PT2559690T (es)
RS (2) RS54876B1 (es)
SG (3) SG161310A1 (es)
SI (2) SI1879573T1 (es)
TW (1) TWI377060B (es)
UA (1) UA99897C2 (es)
WO (1) WO2006122150A1 (es)
ZA (1) ZA200709698B (es)

Families Citing this family (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100406567C (zh) * 2002-01-22 2008-07-30 生物材料公司 生物可降解聚合物的干燥方法
WO2006082030A1 (en) * 2005-02-04 2006-08-10 Ctg Pharma S.R.L. New 4-aminoquinoline derivatives as antimalarials
CA2596509A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
DE102005053947A1 (de) * 2005-11-11 2007-05-16 Univ Ernst Moritz Arndt Neue Arzneimittel
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20070203140A1 (en) * 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP2010501567A (ja) * 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
US20080146624A1 (en) * 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
KR20090053923A (ko) 2006-09-22 2009-05-28 노파르티스 아게 헤테로시클릭 유기 화합물
US20080182882A1 (en) * 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CN101595105B (zh) 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
US8389568B2 (en) * 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
US20090170842A1 (en) 2007-11-14 2009-07-02 University Of Kansas Brca1-based breast or ovarian cancer prevention agents and methods of use
JP5583592B2 (ja) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
WO2009124252A2 (en) * 2008-04-03 2009-10-08 Lankenau Institute For Medical Research Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases
ES2657963T3 (es) 2008-04-17 2018-03-07 Io Biotech Aps Inmunoterapia basada en indolamina 2,3-dioxigenasa
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
CN102639517B (zh) 2009-09-25 2016-05-11 拜耳知识产权有限责任公司 N-(1,2,5-噁二唑-3-基)苯甲酰胺及其作为除草剂的用途
JP2012041325A (ja) * 2010-08-23 2012-03-01 Bayer Cropscience Ag オキサジアゾリノン誘導体およびその有害生物の防除用途
WO2012087234A1 (en) * 2010-12-22 2012-06-28 Idogen Ab A composition comprising at least to compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs
NO2694640T3 (es) * 2011-04-15 2018-03-17
CN104053656A (zh) 2011-11-16 2014-09-17 巴斯夫欧洲公司 取代的1,2,5-噁二唑化合物及其作为除草剂的用途ii
KR20140107280A (ko) * 2011-11-18 2014-09-04 바스프 에스이 치환된 1,2,5-옥사디아졸 화합물 및 이의 제초제 ｉｉｉ 로서의 용도
KR101229365B1 (ko) * 2012-07-02 2013-02-18 대한민국 〔ｚ〕­ｎ­〔３­〔２，４­디플루오로페닐아미노〕­１­〔４­나이트로페닐〕­３­옥소프로프­１­엔­２­일〕­２­메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
JP6327754B2 (ja) 2013-06-21 2018-05-23 クミアイ化学工業株式会社 ２−アミノ−２−ヒドロキシイミノ−ｎ−アルコキシアセトイミドイルシアニドの製造方法およびその製造中間体
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
RU2536041C1 (ru) * 2013-10-11 2014-12-20 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) 3,3'-бис(фтординитрометил-onn-азокси)-4,4'-дифуразаниловый эфир и способ его получения
DK3066085T3 (da) * 2013-11-08 2020-06-02 Incyte Holdings Corp Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
ES2857848T3 (es) 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
CN106535884A (zh) 2014-06-06 2017-03-22 弗雷克萨斯生物科学公司 免疫调节剂
AU2015302908B2 (en) * 2014-08-13 2020-02-13 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
CN105481789B (zh) * 2014-09-15 2020-05-19 中国科学院上海有机化学研究所 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
ES2789331T3 (es) 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
KR20170134980A (ko) 2015-04-03 2017-12-07 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 인돌아민-2,3-디옥시게나제의 억제제
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
JP6801159B2 (ja) 2015-04-21 2020-12-16 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． イミダゾイソインドール誘導体、その製造方法及びその医薬用途
EP3294736B1 (en) 2015-05-11 2020-07-22 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CA2990335A1 (en) * 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
HK1252514A1 (zh) 2015-07-14 2019-05-31 Kyowa Kirin Co., Ltd. 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
EP3954369B1 (en) 2015-07-24 2025-08-20 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
CN108137597A (zh) 2015-07-28 2018-06-08 百时美施贵宝公司 TGFβ受体拮抗剂
WO2017035118A1 (en) 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN106565696B (zh) * 2015-10-09 2020-07-28 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EP3370699A1 (en) 2015-11-04 2018-09-12 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
US20170145103A1 (en) 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
KR102738306B1 (ko) 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
CN106883193B (zh) * 2015-12-15 2021-10-15 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
US10538497B2 (en) 2015-12-15 2020-01-21 Merck Sharp & Dohme Corp. Compounds as indoleamine 2,3-dioxygenase inhibitors
CN106883194A (zh) * 2015-12-16 2017-06-23 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
US9624185B1 (en) * 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
AU2017215424A1 (en) 2016-02-02 2018-08-09 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN107033097B (zh) * 2016-02-04 2022-02-08 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
US11752131B2 (en) * 2016-02-19 2023-09-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of obesity
CN108884104B (zh) * 2016-02-19 2021-01-15 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CN107176933B (zh) * 2016-03-09 2020-10-09 中国科学院上海有机化学研究所 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
JP2019516682A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
US11066383B2 (en) 2016-05-04 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109414420A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019516681A (ja) * 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
AR108586A1 (es) * 2016-06-10 2018-09-05 Lilly Co Eli Compuestos de 2,3-dihidro-1h-indol
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JP2019521166A (ja) 2016-07-20 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
WO2018024208A1 (zh) * 2016-08-02 2018-02-08 南京明德新药研发股份有限公司 Ido1抑制剂及其制备方法和应用
WO2018039430A1 (en) * 2016-08-24 2018-03-01 H. Lee Moffitt Cancer Center & Research Institute, Inc. Radiofluorinated carboximidamides as ido targeting pet tracer for cancer imaging
WO2018039518A1 (en) 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3504185B1 (en) * 2016-08-29 2021-11-24 Merck Sharp & Dohme Corp. Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2018053529A1 (en) 2016-09-19 2018-03-22 University Of South Florida Method of targeting oncolytic viruses to tumors
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
CN107954999B (zh) * 2016-10-17 2023-01-24 上海医药集团股份有限公司 含噁二唑环化合物、制备方法、中间体、组合物及应用
UY37466A (es) 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
CN110139857B (zh) 2016-11-28 2023-07-21 重庆复尚源创医药技术有限公司 作为吲哚胺2,3-双加氧酶抑制剂的亚砜亚胺、磺酰亚胺酰胺、磺酰二亚胺和二酰亚胺磺酰胺化合物
CN106866648B (zh) * 2017-01-03 2019-10-22 中国药科大学 邻苯二甲酰亚胺类吲哚胺-2,3-双加氧酶1抑制剂及其用途
CN106883224B (zh) * 2017-01-03 2019-10-22 中国药科大学 苯并含氮杂环类吲哚胺-2,3-双加氧酶1抑制剂及其用途
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
CN106866571B (zh) * 2017-01-20 2018-06-29 中国药科大学 杂环脲类化合物及其药物组合物和应用
WO2018156443A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Novel substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11034661B2 (en) * 2017-03-29 2021-06-15 Merck Sharp & Dohme Corp. Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors
CN106967004B (zh) * 2017-03-29 2019-09-17 中国药科大学 含脲基的ido1和ido2双重抑制剂、其制法及其医药用途
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
CN108689958B (zh) * 2017-04-05 2021-09-17 南京华威医药科技集团有限公司 一种含有肼基的吲哚胺2,3-双加氧化酶抑制剂
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
CN108727361A (zh) * 2017-04-24 2018-11-02 南京药捷安康生物科技有限公司 吲哚胺2,3-双加氧酶抑制剂与应用
CN108794423B (zh) * 2017-04-27 2022-07-19 鲁南制药集团股份有限公司 亚氨脲衍生物
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109081818B (zh) * 2017-06-14 2022-04-22 南京华威医药科技集团有限公司 新型吲哚胺2,3-双加氧化酶抑制剂
CN109111438B (zh) * 2017-06-26 2021-11-02 正大天晴药业集团股份有限公司 用于ido抑制剂的脒类化合物
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
CN110891942B (zh) * 2017-07-14 2022-06-07 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
KR102709265B1 (ko) 2017-07-28 2024-09-23 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019036657A1 (en) 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
US11667663B2 (en) 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3675877A1 (en) 2017-08-31 2020-07-08 Multimmune GmbH Hsp70 based combination therapy
US20200361919A1 (en) * 2017-09-01 2020-11-19 Nanjing Transthera Biosciences Co. Ltd. Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof
CN108863976B (zh) * 2017-09-11 2022-09-16 郑州泰基鸿诺医药股份有限公司 用作ido调节剂的化合物及其应用
WO2019055786A1 (en) 2017-09-14 2019-03-21 Lankenau Institute For Medical Research METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
EP3694503B1 (en) 2017-10-09 2023-08-02 Merck Sharp & Dohme LLC Novel substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3694502B1 (en) 2017-10-09 2023-08-02 Merck Sharp & Dohme LLC Novel substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11660311B2 (en) 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11427610B2 (en) 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN109678813A (zh) * 2017-10-18 2019-04-26 中国科学院上海有机化学研究所 吲哚胺-2,3-双加氧酶抑制剂盐及其制备方法
CN111542544A (zh) 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
CN109748911B (zh) * 2017-11-06 2022-03-11 中国药科大学 一种含三氮唑的ido抑制剂、其制备方法及其医药用途
JP7167146B2 (ja) 2017-11-06 2022-11-08 ブリストル－マイヤーズ スクイブ カンパニー Ｈｐｋ１阻害剤として有用なイソフラノン化合物
CN107987031A (zh) * 2017-12-01 2018-05-04 华东理工大学 一种靶向吲哚胺-2,3-双加氧酶1氮芥类抑制剂及其制备方法和应用
EP3724177A1 (en) 2017-12-12 2020-10-21 Phenex Discovery Verwaltungs-GmbH Oxalamides as modulators of indoleamine 2,3-dioxygenase
CN108003111A (zh) * 2017-12-14 2018-05-08 华东理工大学 一种hdac1和ido1双靶点抑制剂及其制备方法和应用
CN109942565B (zh) * 2017-12-20 2021-03-26 海创药业股份有限公司 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3697423A4 (en) 2018-01-05 2021-08-11 Dicerna Pharmaceuticals, Inc. REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY
KR20250078626A (ko) 2018-01-12 2025-06-02 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
CN110054622B (zh) * 2018-01-18 2021-02-23 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN108586378B (zh) 2018-01-22 2020-06-19 南京华威医药科技集团有限公司 吲哚胺2,3-双加氧化酶抑制剂及其制备方法和用途
CN110092750B (zh) 2018-01-29 2023-07-21 北京诺诚健华医药科技有限公司 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR20200130362A (ko) 2018-03-08 2020-11-18 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
US20210122757A1 (en) 2018-03-29 2021-04-29 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
US20210147570A1 (en) 2018-04-12 2021-05-20 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
WO2019206800A1 (en) 2018-04-24 2019-10-31 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
PT3814347T (pt) 2018-06-27 2023-07-18 Bristol Myers Squibb Co Compostos de naftiridinona úteis como ativadores de células t
TW202428604A (zh) 2018-07-09 2024-07-16 美商戊瑞治療有限公司 結合至ilt4的抗體
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
US11274150B2 (en) 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
AR117200A1 (es) * 2018-11-30 2021-07-21 Syngenta Participations Ag Derivados de tiazol microbiocidas
CN111689952A (zh) * 2019-03-14 2020-09-22 复旦大学 含硫代四元环结构的2,3-双加氧酶抑制剂及其制备方法和用途
CN111909107B (zh) * 2019-05-10 2023-02-03 药康众拓(江苏)医药科技有限公司 Ido/hdac双重抑制剂及其药物组合物和应用
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN111943906B (zh) * 2019-05-14 2023-12-15 中国医学科学院药物研究所 脒类衍生物、及其制法和药物组合物与用途
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
CN112062732B (zh) * 2019-06-10 2023-10-24 鲁南制药集团股份有限公司 一种ido抑制剂及其组合物、制备方法和用途
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
EP4031575A1 (en) 2019-09-19 2022-07-27 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
WO2021108288A1 (en) 2019-11-26 2021-06-03 Bristol-Myers Squibb Company Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
PT4065582T (pt) 2019-11-26 2025-05-22 Ikena Oncology Inc Derivados polimórficos do carbazol e utilizações dos mesmos
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
CN114846007B (zh) 2019-12-23 2024-11-22 百时美施贵宝公司 可用作t细胞激活剂的经取代的喹唑啉基化合物
KR20220119456A (ko) 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
EP4081522A1 (en) 2019-12-23 2022-11-02 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
BR112022013424A2 (pt) 2020-01-06 2022-12-13 Hifibio Hk Ltd Anticorpo anti-tnfr2 e seus usos
CN111138425A (zh) * 2020-01-06 2020-05-12 中国药科大学 三氮唑类衍生物及其制备方法与用途
KR20220123105A (ko) 2020-01-07 2022-09-05 하이파이바이오 (에이치케이) 리미티드 항-갈렉틴-9 항체 및 그것의 용도
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
CN116724051A (zh) 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP4262986A1 (en) 2020-12-16 2023-10-25 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
JP7821808B2 (ja) 2021-02-12 2026-02-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための二環式テトラヒドロアゼピン誘導体
CN113105366B (zh) * 2021-03-04 2022-05-24 中国药科大学 一类含苯基羟肟结构衍生物及其制法与用途
JP2024510176A (ja) 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
BR112023020410A2 (pt) 2021-04-05 2023-11-28 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila
KR20240083168A (ko) 2021-07-14 2024-06-11 블루프린트 메디신즈 코포레이션 Map4k1 저해제로서의 헤테로사이클 화합물
US20240336630A1 (en) 2021-07-15 2024-10-10 Blueprint Medicines Corporation Map4k1 inhibitors
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
EP4472963A1 (en) 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
US20260049068A1 (en) 2022-08-08 2026-02-19 Bristol-Myers Squibb Company Substituted Tetrazolyl Compounds Useful as T Cell Activators
KR20250046310A (ko) 2022-08-09 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물
TW202417001A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫吖呯衍生物
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
CR20250043A (es) 2022-08-11 2025-03-25 Hoffmann La Roche Derivados bicíclicos de tetrahidrotiazepina
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
EP4709712A1 (en) 2023-05-10 2026-03-18 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
EP4724149A1 (en) 2023-06-07 2026-04-15 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
AU2024314878A1 (en) 2023-06-23 2026-01-22 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
IL326828A (en) 2023-09-02 2026-04-01 Bristol Myers Squibb Co Piperidine-2,6-dione azatidinyl oxoisoindolinyl substituted compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
TW202535865A (zh) 2023-10-31 2025-09-16 美商必治妥美雅史谷比公司 泛素特異性加工蛋白酶1 (usp1) 化合物
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026035787A1 (en) 2024-08-07 2026-02-12 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) macrocyles
CN118908989B (zh) * 2024-10-10 2024-12-17 江苏长泰药业股份有限公司 一种用于预防肺结节恶性转化的丙酮酸盐衍生物纳米雾化剂及其制备方法
WO2026080794A1 (en) 2024-10-11 2026-04-16 Bristol-Myers Squibb Company Chemical compounds useful for degrading proteins

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236855A (en) 1964-01-17 1966-02-22 Merck & Co Inc Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en) 1964-02-19 1967-11-21 Sterling Drug Inc 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
DE1453353A1 (de) 1964-02-20 1970-01-15 Nottmeyer Maschf Heinrich Maschine zum Einpressen von Duebeln in eine vorgebohrte Platte oder dergleichen Werkstueck
US3286855A (en) 1965-06-01 1966-11-22 Standard Trailer Company Crane extension and resulting crane assembly
US3553228A (en) 1967-09-26 1971-01-05 Colgate Palmolive Co 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (de) 1970-08-17 1972-02-24 Fahlberg List Veb Neue herbizide Mittel
US3948928A (en) 1972-03-17 1976-04-06 Dainippon Pharmaceutical Co., Ltd. 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (es) 1973-09-05 1981-05-16
FR2323683A1 (fr) 1975-09-11 1977-04-08 Philagro Sa Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent
CA1080234A (en) 1975-09-11 1980-06-24 Daniel Farge Derivatives of amidoximes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4323681A (en) * 1980-09-29 1982-04-06 American Home Products Corporation 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS58208275A (ja) * 1982-05-20 1983-12-03 Lion Corp ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
EP0132680B1 (de) 1983-07-22 1987-01-28 Bayer Ag Substituierte Furazane
US4507485A (en) 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (ja) 1984-03-13 1985-10-02 Toyo Jozo Co Ltd シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法
JPS6259283A (ja) 1985-09-10 1987-03-14 Kaken Pharmaceut Co Ltd セフアロスポリン化合物
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP2696342B2 (ja) * 1988-06-27 1998-01-14 日本曹達株式会社 アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
DE68901424D1 (de) 1988-07-05 1992-06-11 Akzo Nv Verbindungen mit bronchodilatatorischer aktivitaet.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH0420710A (ja) 1990-05-12 1992-01-24 Hitachi Home Tec Ltd ポットバーナの運転制御装置
JPH04297449A (ja) 1991-03-27 1992-10-21 Hokko Chem Ind Co Ltd Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤
JPH05186458A (ja) 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP2709677B2 (ja) * 1992-06-19 1998-02-04 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
FR2720396B1 (fr) 1994-05-27 1996-06-28 Adir Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5731315A (en) 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
NZ319673A (en) * 1995-10-17 2000-06-23 Astra Pharma Prod Quinazoline compounds for inflammatory disorders such rheumatoid arthritis or osteoarthritis
WO1997030047A1 (en) * 1996-02-17 1997-08-21 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en) 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
JPH11171702A (ja) 1997-09-24 1999-06-29 Takeda Chem Ind Ltd 害虫防除方法
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
NZ505002A (en) 1997-12-10 2001-11-30 Dainippon Ink & Chemicals 1,2,5-oxadiazolyl, 1,2,5-thiadiazolyl or 1,2,3-thiadiazolyl oxime derivatives substituted by another heterocyclic group useful as agricultural chemicals
ATE221529T1 (de) 1998-06-02 2002-08-15 Takeda Chemical Industries Ltd Oxadiazolinderivate und ihre verwendung als insektizide
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
WO2000052001A1 (en) 1999-03-03 2000-09-08 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
NZ515026A (en) 1999-04-09 2003-10-31 Abbott Gmbh & Co Heterocyclic amidine derivatives useful as prodrugs of thrombin inhibitors
CN1164574C (zh) 1999-05-24 2004-09-01 三菱制药株式会社 苯氧基丙胺类化合物
JP2001158786A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 哺乳動物の外部寄生虫防除剤
JP2001158785A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 農薬組成物
WO2001051456A2 (en) 2000-01-13 2001-07-19 Tularik Inc. Antibacterial agents
JP2001233861A (ja) 2000-02-22 2001-08-28 Ube Ind Ltd ピラゾールオキシム化合物、その製法及び用途
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
UA75145C2 (en) 2001-06-18 2006-03-15 Applied Research Systems Pyrrolidine oxadiazole and thiadiazole derivatives, pharmaceutical composition based thereon, a method for producing thereof (variants)
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
WO2003035092A1 (en) * 2001-10-26 2003-05-01 Angiolab Inc. Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
ES2269793T3 (es) 2001-10-30 2007-04-01 Novartis Ag Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
US20040127492A1 (en) 2002-02-19 2004-07-01 Pharmacia Corporation Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
HRP20041220A2 (hr) 2002-05-28 2006-04-30 3-Dimensional Pharmaceuticals Novi tiofen amidini, njihovi pripravci i postupci liječenja komplementom posredovanih bolesti i stanja
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
JP4020710B2 (ja) 2002-06-25 2007-12-12 株式会社ミツバ ドアミラーセットプレート
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7015321B2 (en) 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2004267094A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CA2579207C (en) 2004-09-08 2011-10-18 Mitsubishi Pharma Corporation Morpholine compound
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
WO2007005807A2 (en) 2005-06-30 2007-01-11 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
DE102005060466A1 (de) 2005-12-17 2007-06-28 Bayer Cropscience Ag Carboxamide
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (ja) 2006-05-12 2009-07-15 株式会社サクラクレパス 墨汁
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080182882A1 (en) 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR102051881B1 (ko) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CA2921203C (en) 2013-07-12 2021-07-27 Nippon Chemiphar Co., Ltd. Diazepinedione derivatives and compositions thereof useful as p2x4 receptor antagonist
DK3066085T3 (da) 2013-11-08 2020-06-02 Incyte Holdings Corp Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
US20170037125A1 (en) 2014-02-04 2017-02-09 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
EP3370699A1 (en) 2015-11-04 2018-09-12 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
EP4007602A1 (en) 2019-08-01 2022-06-08 Incyte Corporation A dosing regimen for an ido inhibitor
US12594312B2 (en) 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection

Also Published As

Publication number Publication date
US20190210985A1 (en) 2019-07-11
HUE029214T2 (en) 2017-02-28
PT1879573E (pt) 2013-03-25
DK2559690T3 (en) 2016-04-25
WO2006122150A1 (en) 2006-11-16
DK1879573T3 (da) 2013-02-25
SG161310A1 (en) 2010-05-27
AU2006244068B2 (en) 2012-06-14
US20110311479A1 (en) 2011-12-22
JP4990270B2 (ja) 2012-08-01
HK1117392A1 (en) 2009-01-16
ZA200709698B (en) 2008-11-26
ES2401482T3 (es) 2013-04-22
RS54876B1 (sr) 2016-10-31
NZ562919A (en) 2011-04-29
NO340487B1 (no) 2017-05-02
CA2606783C (en) 2014-03-25
HRP20160537T1 (hr) 2016-06-17
EP3085697A1 (en) 2016-10-26
US20180030006A1 (en) 2018-02-01
JP5615308B2 (ja) 2014-10-29
IL186957A (en) 2014-04-30
EP1879573A1 (en) 2008-01-23
KR20130109263A (ko) 2013-10-07
SI2559690T1 (sl) 2016-06-30
CY1117681T1 (el) 2017-05-17
PL1879573T3 (pl) 2013-05-31
BRPI0608604B8 (pt) 2021-05-25
EP1879573B1 (en) 2012-12-19
AU2006244068B9 (en) 2012-10-25
PT2559690T (pt) 2016-07-07
BRPI0608604B1 (pt) 2020-11-17
SI1879573T1 (sl) 2013-04-30
SG10201809390QA (en) 2018-11-29
JP2012140450A (ja) 2012-07-26
NO20170633A1 (no) 2008-02-07
EP2559690B1 (en) 2016-03-30
BR122020016659B8 (pt) 2021-07-27
EP2559690A1 (en) 2013-02-20
EA026785B1 (ru) 2017-05-31
ME02461B (me) 2017-02-20
MX2007013977A (es) 2008-02-05
MY153424A (en) 2015-02-13
EP1879573A4 (en) 2009-07-08
CN101212967A (zh) 2008-07-02
KR101386494B1 (ko) 2014-04-24
KR20080005954A (ko) 2008-01-15
CY1113989T1 (el) 2016-07-27
BRPI0608604A2 (pt) 2010-01-26
IL186957A0 (en) 2008-02-09
US8034953B2 (en) 2011-10-11
BR122020016659B1 (pt) 2021-03-16
US20130123246A1 (en) 2013-05-16
NO342140B1 (no) 2018-03-26
US10208002B2 (en) 2019-02-19
HRP20130220T1 (hr) 2013-04-30
TWI377060B (en) 2012-11-21
GEP20217221B (en) 2021-02-10
JP2008540548A (ja) 2008-11-20
TW200719892A (en) 2007-06-01
CN103130735B (zh) 2016-08-03
US20060258719A1 (en) 2006-11-16
AR054271A1 (es) 2007-06-13
US8846726B2 (en) 2014-09-30
US8372870B2 (en) 2013-02-12
EA200702455A1 (ru) 2008-04-28
UA99897C2 (en) 2012-10-25
US11192868B2 (en) 2021-12-07
CA2606783A1 (en) 2006-11-16
NO20075693L (no) 2008-02-07
IL232313A (en) 2016-05-31
RS52711B (sr) 2013-08-30
CN103130735A (zh) 2013-06-05
SG195607A1 (en) 2013-12-30
US20140377292A1 (en) 2014-12-25
PL2559690T3 (pl) 2016-09-30
KR101562549B1 (ko) 2015-10-23
HK1182381A1 (en) 2013-11-29
IL232313A0 (en) 2014-06-30
CR9485A (es) 2008-02-20
AU2006244068A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ES2578404T3 (es) Moduladores de la indolamina 2,3-dioxigenasa, y métodos de uso de los mismos
AU2009253797B2 (en) N-piperidinyl acetamide derivatives as calcium channel blockers
JP5982705B2 (ja) 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
US7105567B2 (en) 3-substituted urea derivatives and medicinal use thereof
JP2010501587A5 (es)
JP2005523920A5 (es)
BG103181A (bg) Използване на непептидни nk3 антагонисти за лечение на кожни заболявания и сърбеж
JPWO2002014265A1 (ja) 新規３置換尿素誘導体およびその医薬としての用途
CN1341100A (zh) 3－苯基吡啶衍生物及其作为nk－1受体拮抗剂的应用
WO2004010943A2 (en) Substituted benzanilides as modulators of the ccr5 receptor
RU2011129786A (ru) Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний
JPWO2004011430A1 (ja) ナトリウムチャネル阻害剤
KR20100119757A (ko) 바닐로이드 수용체 길항체로서의 신규 화합물, 이의 이성질체 또는 약제학적으로 허용가능한 염, 및 이를 함유하는 약학 조성물
BRPI0612216A2 (pt) uso de um composto, uso de um ligante do receptor h3 e combinação
MX2007006739A (es) Compuestos de aminobenzofenona sustituidos con triazol.
CN102137851B (zh) 作为香草素受体拮抗剂的化合物、其异构体或其药学可接受的盐以及包含它们的药物组合物
JP2014001142A (ja) シクロアルカン化合物
JP2005531594A (ja) 慢性苦痛の治療用トリプルモノアミン再取り込み阻害剤
RU2415136C2 (ru) Новые производные бензотиазолона
WO2021182596A1 (ja) 上眼瞼溝深化改善剤
HK1240844A1 (en) N-piperidinyl acetamide derivatives as calcium channel blockers
HK1117392B (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
HK1182381B (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same